Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Lets have some Valuation fun...
View:
Post by beechguy on Mar 25, 2015 11:10pm

Lets have some Valuation fun...

It's hard to fathom w/ our gruesome chart, but every ridiculous high flier, had a miserable stock chart at some point. Since fantasizing can be fun, here we go... Here's (ir)rationalization for a 214 (yeah I said it) bagger from the .14 all time low (this is for you Rube). If you assume FDA approval happens and (there is no real reason to think it won't - MCNA's efficacy is 150% higher than the already approved Valrubicin with only 1.5% of patients experiencing "mild to moderate side effects" (Valrubicin is > 30%). Lets also assume the independent analysis of 400mm peak revenue in the US is a fair number. (at 45k per patient, that is 8800 patients - only 20% penetration of refractory to BCG patients - who's only real treatment remaining is bladder removal). That is with no off label, no EU, no South America, no Asia and no pre-existing BC patients of which there is 700,000 in North America alone. So really the peak revenue could end up being well over a billion world wide (not a year after FDA approval, but 5 or 6 years in perhaps) So if we had a billion in revenue and used the average of the last several biotech tech deals I read up on, (5 times peak revenue) our valuation could be (assuming 210mm shares O/S and no more dilution - I know a stretch) $24 USD /share ($30 CDN). It all starts when we break through the seemingly impenetrable wall at .40. When it does, thing should get very interesting very fast. Hang in there, it's going to get fun soon methinks. GLTA beech
Comment by ChiefCommander1 on Mar 25, 2015 11:19pm
This post has been removed in accordance with Community Policy
Comment by 18tee20 on Mar 26, 2015 4:28am
More valuation fun with MCNA Beech...  Obviously a $30 CDN valuation is quite the stretch with everything going perfectly, but isn't it fair to say that there is also quite a lot of additional value in whoever takes over the MCNA platform?   As you noted, your valuation does not even include any off label use, no EU, No South America, no Asia, and no pre-existing BC patients ...more  
Comment by Jasl on Mar 26, 2015 8:14am
Immunocidin was the drug. I was just searching for that two days ago and can't find it for sale by anyone. It's not on vet quinonel web page.  Does anybody remember who owns the rights to immunocidin.  Thanks jasl
Comment by 18tee20 on Mar 26, 2015 11:49am
As I recall, the subject of whether the rights to selling Immunocidin along with all the other animal health products at the time that portion of the business was sold to Quinonel was never specifically addressed by Bioniche at the time.  As I was curious about that aspect at the time of animal health sale, I was alert to any announcement about Immunocin and/or MCNA rights for animal health ...more  
Comment by blartar on Mar 26, 2015 9:52am
RIGHT ON BEECH   I agree about breaking above .40 ( when we break through the seemingly impenetrable wall at .40. When it does, thing should get very interesting very fast ) I'm just hoping that we break .40 +  after the BLA submission or before so the Sept/2015 wrts. come into play to supply the company with CASH. then they won't have an excuse to do a PP to enrich ...more  
Comment by DamnYankees on Mar 26, 2015 10:08am
Could be a potential partner or buyer holding it down Blartar. It could be the MM who wants the next financing at these levels. It could be 2 school kids with their lunch money. It doesn't take much to suppress a stock that no one is aware of or cares to investigate. I have also been told that current owners are all overweight and tapped out. If that is the case they might want to hire an IR ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities